Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 3Phase 3 2Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 2Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 1

Interventions

Magnetic Resonance Spectroscopy 5pembrolizumab 4Biopsy 4durvalumab 3atezolizumab 3Radiotherapy 3Radiosurgery 3Cyclophosphamide 3Bevacizumab 3palbociclib 2niraparib 2abemaciclib 2Trastuzumab 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Melphalan 2Letrozole 2Ketamine 2Irinotecan 2Hydrocortisone 2Gemcitabine 2Ferrosoferric Oxide 2Dexamethasone 2Curcumin 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Topotecan × Clear all
NCT03193463 2019-03-01

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡